Volume 15, Issue 3 pp. 315-328

Long-Term Recurrence Rates in Previously Untreated (Primary) Basal Cell Carcinoma: Implications for Patient Follow-Up

DAN E. ROWE M.D.

DAN E. ROWE M.D.

Dan E. Rowe, M.D., Resident, and Calvin L. Day, Jr., M.D., Clinical Associate Professor of Medicine (Dermatology), are from the University of Texas Health Science Center at San Antonio, Texas.

Search for more papers by this author
RAYMOND J. CARROLL Ph.D.

RAYMOND J. CARROLL Ph.D.

Dan E. Rowe, M.D., Resident, and Calvin L. Day, Jr., M.D., Clinical Associate Professor of Medicine (Dermatology), are from the University of Texas Health Science Center at San Antonio, Texas.

Search for more papers by this author
CALVIN L. JR. DAY M.D.

Corresponding Author

CALVIN L. JR. DAY M.D.

Raymond J. Carroll, Ph.D., is Professor and Head of Statistics, Texas A&M University, College Station, Texas.

Address reprint requests to Calvin L. Day, Jr., M.D., 7711 Louis Pasteur, 104 Oak Hills Medical Building, San Antonio, TX 78229.Search for more papers by this author
First published: March 1989
Citations: 628

Abstract

Abstract. We reviewed all studies (since 1947) reporting recurrence rates for treatment of primary (previously untreated) basal cell carcinomas using surgical excision, radiotherapy, cryotherapy, curettage and electrodesiccation, and Mohs micrographic surgery. Our findings indicate that recurrences following treatment of primary basal cell carcinoma appear later than is generally acknowledged in the literature. We found that less than one-third of all recurrences appear in the first year following treatment; only 50% appear within the first 2 years following treatment; and only 66%, or nearly two-thirds, appear within the first 3 years following treatment. A good rule of thumb is that the 10-year recurrence rate is double, or 2 times, that of the 2-year recurrence rate. Furthermore, 18% of recurrences appear between the fifth and tenth year following treatment. These results held true, irrespective of treatment modality examined. Seventy-two studies reporting short-term recurrence rates (follow-up less than 5 years) had a weighted average recurrence rate of 4.2%, whereas 34 long-term studies (follow-up of 5 years) had a weighted average recurrence rate of 8.7%, or more than 2 times the short-term rate. Five-year recurrence rates by treatment modality are as follows: Mohs micrographic surgery 1.0%, surgical excision 10.1%, curettage and electrodesiccation 7.7%, radiation therapy 8.7%, and cryosurgery 7.5%. We conclude that the reporting of recurrence rate data for basal cell carcinoma should be standardized using 5-year life table analysis, and even more important is our conclusion that lifetime follow-up is necessary after treatment of primary basal cell carcinoma in order to detect both recurrences and new primaries.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.